Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates

使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗

基本信息

项目摘要

Breast cancer is the most commonly diagnosed cancer in women and is a second leading cause of death among woman. Despite the significant progress in molecular understanding and personalized therapies of breast cancer, this disease in progressed metastatic stage remains incurable and treatment options available to patients provide only modest survival benefit. Efficacy of existing systemic chemotherapy is limited in delivery, access and penetration into solid tumors, as well as by toxicity to patients. Thus, to develop more effective and safer therapies of breast cancer, it is necessary to implement an efficient targeted drug delivery system. Caveolae at the surface of tumor endothelial cells act as a transendothelial transport system that actively pumps targeted antibodies from the blood circulation into the tumor tissue. Our findings support that targeting caveolae provides a platform for rapid pumping of targeted antibodies with attached cargo specifically into breast tumors at concentrations greatly exceeding maximum levels in the blood. Using these recent findings, we intend to target antibody drug conjugates (ADC) of DM1 maytansinoid, one of the most potent anticancer drugs to target truncated form of Annexin A1 in tumor endothelial caveolae in order to deliver this powerful therapeutic effectively inside of breast tumors. We have demonstrated that AnnA1 is expressed in the vasculature and caveolae of human tumors. Recently, we have generated humanized antibody against AnnA1 (hAnnA1) and our preliminary experiments demonstrate strong therapeutic response of breast cancer to hAnnA1 conjugated to DM1 (hAnnA1-DM1 ADC). We hypothesize that by pumping targeted antibodies armed with DM1 drug into breast tumors, caveolae can rapidly and specifically accumulate this therapeutic agent inside tumors, leading to tumor destruction with significantly reduced toxicity. We propose these Specific Aims: Aim 1. To generate and characterize ADCs. We will prepare series of conjugates with DM1 drug covalently attached to hAnnA1 antibody using non-cleavable and cleavable linkers. Based on the screening in Aim2, we will generate THIOMAB hAnnA1 with select linker chemistry. Aim 2. Screening for optimal linker chemistry, production, validation and pharmacokinetic analysis of tumor vascular caveolae-targeted DM1 THIOMAB ADC in rodent tumor model of breast cancer. These studies will enable implementing optimal linker chemistry to develop ADC with site-specific attachment of DM1. Aim 3. Evaluation of therapeutic efficacy of the tumor vascular caveolae-targeted DM1 ADCs in clinically-relevant models of breast cancer. Therapeutic studies in clinically-relevant orthotopic models of breast cancer, including intravital microscopy model of human tumor spheroids engrafted into human breast tissue, and patient-derived breast cancer xenografts, including triple-negative and HER2+ models, will provide platform to evaluate novel hAnnA1-DM1 ADC therapy. The proposed project will help to establish framework for clinical translation of tumor-caveolae targeted ADC for treatment of breast cancer.
乳腺癌是妇女中最常见的癌症,也是第二大死亡原因

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Adrian Chrastina其他文献

Adrian Chrastina的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Adrian Chrastina', 18)}}的其他基金

Tumor Imaging Core
肿瘤成像核心
  • 批准号:
    10655416
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:
Tumor Imaging Core
肿瘤成像核心
  • 批准号:
    10251319
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:
Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates
使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗
  • 批准号:
    10693126
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:
Tumor Imaging Core
肿瘤成像核心
  • 批准号:
    9974492
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:
Tumor caveolae-targeted systemic therapy of breast cancer with antibody drug conjugates
使用抗体药物缀合物对乳腺癌进行肿瘤小窝靶向全身治疗
  • 批准号:
    10472546
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:
Tumor Imaging Core
肿瘤成像核心
  • 批准号:
    10449310
  • 财政年份:
    2019
  • 资助金额:
    $ 42.32万
  • 项目类别:

相似国自然基金

靶向Annexin A1蛋白预防CAR-T细胞治疗后BCMA阴性多发性骨髓瘤复发的机制研究
  • 批准号:
    82370201
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
Annexin A1通过IFN-γ通路正向调控PD-L1介导肺腺癌免疫逃逸的机制研究
  • 批准号:
    82172716
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
外源性尿酸调控SP1-Annexin a1在大鼠肝性脑病中的保护作用及机制研究
  • 批准号:
    82060128
  • 批准年份:
    2020
  • 资助金额:
    34 万元
  • 项目类别:
    地区科学基金项目
Annexin A1 调控 Notch1/Smad2/p15 信号轴促进急性髓系白血病细胞增殖的机制研究
  • 批准号:
    81770176
  • 批准年份:
    2017
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
Annexin A1通过调控TGF-β 受体内吞促进人卵巢癌细胞增殖的机制研究
  • 批准号:
    81672577
  • 批准年份:
    2016
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
膜联蛋白Annexin A1与Annexin A7在脑出血后继发性脑损伤中的作用机制研究
  • 批准号:
    81571115
  • 批准年份:
    2015
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
Annexin A1对婴幼儿体外循环术后急性肺损伤的保护研究
  • 批准号:
    81400309
  • 批准年份:
    2014
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
哺乳动物雷帕霉素靶蛋白(mTOR)介导膜联蛋白A1(Annexin A1)调控衰老相关胰岛β细胞功能下降的研究
  • 批准号:
    81300265
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
Annexin A1在头颈鳞癌EGF相关ERK/MAPK信号通路中的作用机制
  • 批准号:
    81272979
  • 批准年份:
    2012
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目
Annexin A1表达下调/缺失在鼻咽癌放疗抵抗中的作用及其分子机制研究
  • 批准号:
    81272959
  • 批准年份:
    2012
  • 资助金额:
    78.0 万元
  • 项目类别:
    面上项目

相似海外基金

Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
  • 批准号:
    10343330
  • 财政年份:
    2021
  • 资助金额:
    $ 42.32万
  • 项目类别:
Study on the role of annexin A1 in the regulation of gonadotropin secretion from the pituitary gland
膜联蛋白A1对垂体促性腺激素分泌调节作用的研究
  • 批准号:
    21K05964
  • 财政年份:
    2021
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel mitochondrial protective properties of annexin A1
膜联蛋白 A1 的新型线粒体保护特性
  • 批准号:
    10661073
  • 财政年份:
    2021
  • 资助金额:
    $ 42.32万
  • 项目类别:
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
  • 批准号:
    nhmrc : GNT1081770
  • 财政年份:
    2015
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Project Grants
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
ANNEXIN-A1 模拟物:一种针对糖尿病心脏并发症的新型治疗方法
  • 批准号:
    nhmrc : 1081770
  • 财政年份:
    2015
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Project Grants
Role of the downstream mediator of glucocorticoids, annexin A1, in the repair process of acute kidney injury
糖皮质激素下游介质膜联蛋白A1在急性肾损伤修复过程中的作用
  • 批准号:
    252481273
  • 财政年份:
    2014
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Research Units
Annexin-A1 Agonists Rescue Cardiac Contractile Function After Myocardial Infarction
膜联蛋白 A1 激动剂可挽救心肌梗塞后的心脏收缩功能
  • 批准号:
    nhmrc : 1045140
  • 财政年份:
    2013
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Project Grants
Targeted drug delivery to tumor vasculature by annexin A1 binding peptide
通过膜联蛋白 A1 结合肽将药物靶向递送至肿瘤脉管系统
  • 批准号:
    23791737
  • 财政年份:
    2011
  • 资助金额:
    $ 42.32万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了